Given the oncogenic role for CDC20-APC/C in tumor progression as well as its role in drug resistance, the inhibition of CDC20-APC/C activity or the induced degradation of CDC20 are emerging as alternative therapeutic strategies to control cancer [83, 84]. This evidence concerns the gene APC and neoplasm.